Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medicis Pharmaceutical, a US based specialty pharma firm focusing primarily on the treatment of dermatological and aesthetic conditions, and Anacor Pharmaceuticals has entered into a R&D agreement to discover and develop boron-based small molecule compounds for the treatment of acne.
Subscribe to our email newsletter
Anacor will receive a $7m upfront payment from Medicis and will be primarily responsible for discovering and conducting early development of product candidates which utilize Anacor’s proprietary boron chemistry platform.
Medicis will have an option to obtain an exclusive license for products covered by the agreement.
Anacor will be eligible for future research, development, regulatory and sales milestones of up to $153m, as well as high single-digit to low double-digit royalties on sales by Medicis.
Medicis will be responsible for further development and commercialization of the licensed products on a worldwide basis.